| scholarly article | Q13442814 |
| P50 | author | Shahrokh Shariat | Q7462263 |
| P2093 | author name string | Michael Jewett | |
| Neil Fleshner | |||
| Alexandre R Zlotta | |||
| Sandrine Rorive | |||
| Mischel Neill | |||
| Peter J Bostrom | |||
| Claude Schulman | |||
| Michel Petein | |||
| Thierry Roumeguere | |||
| Sultan S Alkhateeb | |||
| Bas Van Rhijn | |||
| David M Kakiashvili | |||
| Sally Hanna | |||
| Sas Bar-Moshe | |||
| P2860 | cites work | Cyclin D1 expression in papillary superficial bladder cancer: its association with other cell cycle-associated proteins, cell proliferation and clinical outcome | Q77537658 |
| Contemporary management of stage T1 transitional cell carcinoma of the bladder | Q77816685 | ||
| p53 mutations in bladder tumors inactivate the transactivation of the p21 and Bax genes, and have a predictive value for the clinical outcome after bacillus Calmette-Guerin therapy | Q77914315 | ||
| Cyclin D1 overexpression lacks prognostic significance in superficial urinary bladder cancer | Q77976619 | ||
| A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival | Q78645453 | ||
| Cell-cycle checkpoints and cancer | Q28293996 | ||
| Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyond | Q28388487 | ||
| Multivariate analysis of the prognostic factors of primary superficial bladder cancer | Q33799104 | ||
| P53 as a prognostic marker for bladder cancer: a meta-analysis and review. | Q36243745 | ||
| P21 and p27: roles in carcinogenesis and drug resistance | Q37184060 | ||
| Combining a molecular profile with a clinical and pathological profile: biostatistical considerations | Q37279010 | ||
| Biomarkers in bladder cancer. | Q37605984 | ||
| Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma | Q38434546 | ||
| Metallothionein expression as prognostic factor for transitional cell carcinoma of bladder | Q38438671 | ||
| Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma | Q38448798 | ||
| p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer | Q38448806 | ||
| Induction of WAF1/CIP1 by a p53-independent pathway | Q42796161 | ||
| Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer | Q44009131 | ||
| Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity | Q44246166 | ||
| Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value | Q44637945 | ||
| Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy | Q44954690 | ||
| Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1-S modulators (p53, p21Waf1, p27kip1, Cyclin D1, and Cyclin D3) and proliferation index (ki67-MIB1). | Q47770673 | ||
| Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy | Q47785950 | ||
| Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. | Q51953901 | ||
| Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. | Q53563491 | ||
| Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis. | Q53601758 | ||
| Humoral response against heat shock proteins and other mycobacterial antigens after intravesical treatment with bacille Calmette-Guérin (BCG) in patients with superficial bladder cancer. | Q54563320 | ||
| Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer | Q56903095 | ||
| Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials | Q64112022 | ||
| Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin | Q73149255 | ||
| Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin | Q73753934 | ||
| Reproducibility of p53 immunohistochemistry in bladder tumors. National Cancer Institute, Bladder Tumor Marker Network | Q73803414 | ||
| p53 and ki67 expression as prognostic factors for cancer-related survival in stage T1 transitional cell bladder carcinoma | Q74325657 | ||
| Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy | Q74449994 | ||
| Bcl-2 and p53 expressions in invasive bladder cancers | Q74528560 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 119-126 | |
| P577 | publication date | 2011-09-01 | |
| P1433 | published in | Urology Annals | Q15817347 |
| P1476 | title | Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guérin | |
| P478 | volume | 3 |
| Q36205304 | CD73 Predicts Favorable Prognosis in Patients with Nonmuscle-Invasive Urothelial Bladder Cancer. |
| Q38259206 | Considerations on the use of urine markers in the management of patients with high-grade non-muscle-invasive bladder cancer. |
| Q84582498 | Expression of MMP-9 and WAVE3 in colorectal cancer and its relationship to clinicopathological features |
| Q55109644 | Harnblasenkrebs |
| Q91794064 | Molecular markers in bladder cancer |
| Q38520403 | Molecular markers in bladder cancer: Novel research frontiers |
| Q38230912 | Predictive markers in bladder cancer: do we have molecular markers ready for clinical use? |
| Q53783227 | Prognostic value of ki67 in BCG-treated non-muscle invasive bladder cancer: a meta-analysis and systematic review. |
| Q41948992 | Who needs numbers more: patients or doctors? |
| Q35572365 | p53 Status correlates with the risk of recurrence in non-muscle invasive bladder cancers treated with Bacillus Calmette-Guérin: a meta-analysis |
Search more.